Who Optimizes SG&A Costs Better? Amgen Inc. or Sarepta Therapeutics, Inc.

Optimizing SG&A Costs: Amgen Inc. vs. Sarepta Therapeutics, Inc.

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Amgen Inc. and Sarepta Therapeutics, Inc. have demonstrated contrasting approaches to SG&A cost management. From 2014 to 2023, Amgen's SG&A expenses have seen a steady increase, peaking at approximately $6.2 billion in 2023, reflecting a 31% rise from 2014. In contrast, Sarepta Therapeutics, Inc. has shown a more dramatic increase, with SG&A expenses growing nearly tenfold, from around $49 million in 2014 to $482 million in 2023. This stark difference highlights Amgen's more stable cost management strategy compared to Sarepta's rapid expansion. As investors and industry analysts evaluate these trends, understanding the implications of SG&A optimization becomes essential for assessing long-term financial health and strategic positioning.